Q2 EPS Estimate for Allogene Therapeutics Raised by Analyst

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities research analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of Allogene Therapeutics in a report issued on Monday, June 2nd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their prior forecast of ($0.28). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics' Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.06) EPS.

ALLO has been the subject of a number of other research reports. Robert W. Baird dropped their price target on Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday, May 14th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Canaccord Genuity Group restated a "buy" rating and issued a $14.00 target price on shares of Allogene Therapeutics in a research note on Friday, March 14th. Citizens Jmp lowered Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 14th. Finally, Citigroup decreased their price objective on Allogene Therapeutics from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.44.

Allogene Therapeutics Price Performance

NASDAQ:ALLO traded up $0.13 during mid-day trading on Wednesday, reaching $1.42. 3,475,725 shares of the company's stock traded hands, compared to its average volume of 3,324,960. The company has a 50 day moving average price of $1.34 and a 200-day moving average price of $1.75. The firm has a market capitalization of $310.60 million, a price-to-earnings ratio of -0.91 and a beta of 0.60. Allogene Therapeutics has a 12-month low of $0.86 and a 12-month high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.28).

Insider Buying and Selling

In other news, CEO David D. Chang sold 46,668 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares of the company's stock, valued at approximately $10,342,075.24. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 61,757 shares of company stock worth $115,873. Corporate insiders own 13.20% of the company's stock.

Institutional Trading of Allogene Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harold Davidson & Associates Inc. grew its stake in shares of Allogene Therapeutics by 8.5% during the first quarter. Harold Davidson & Associates Inc. now owns 252,350 shares of the company's stock valued at $368,000 after buying an additional 19,735 shares during the last quarter. Jane Street Group LLC grew its stake in Allogene Therapeutics by 578.7% in the 1st quarter. Jane Street Group LLC now owns 1,116,681 shares of the company's stock worth $1,630,000 after acquiring an additional 952,158 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock worth $8,547,000 after acquiring an additional 3,747,397 shares during the period. Curi RMB Capital LLC increased its position in shares of Allogene Therapeutics by 31.0% during the first quarter. Curi RMB Capital LLC now owns 195,890 shares of the company's stock worth $286,000 after acquiring an additional 46,313 shares during the period. Finally, AQR Capital Management LLC bought a new stake in shares of Allogene Therapeutics during the first quarter valued at approximately $85,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).